Pipeline

An indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer’s tafamidis in frontline…

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, e…

Partner Therapeutics has received FDA approval for Bizengri to treat adults with advanced, unresectable or met…

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic …

After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same sin…

Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the bi…